Clinical Trial Update: An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating safety and efficacy of recombinant Factor VIII in adults with severe Hemophilia A; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• recombinant Factor VIII (Factor VIII, recombinant)

Snippet

Sponsor: CSL Behring | Conditions: Hemophilia A, Severe Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2021-10-27